Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02230969




Registration number
NCT02230969
Ethics application status
Date submitted
29/08/2014
Date registered
3/09/2014
Date last updated
26/09/2022

Titles & IDs
Public title
Plegridy Observational Program
Scientific title
Plegridy™ (Peginterferon ß-1a) Real World Effectiveness and Safety Observational Program
Secondary ID [1] 0 0
105MS401
Universal Trial Number (UTN)
Trial acronym
POP
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing Forms of Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Drugs - peginterferon beta-1a

peginterferon beta-1a - Plegridy will not be supplied for this study. The study will collect data in an observational manner from participants who are prescribed Plegridy by physicians, according to the approved label in the respective country.


Treatment: Drugs: peginterferon beta-1a
Administered as specified in the treatment arm
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety as measured by the incidence proportion of SAEs
Timepoint [1] 0 0
Up to 5 years
Primary outcome [2] 0 0
Safety as measured by the incidence rate of SAEs
Timepoint [2] 0 0
Up to 5 years
Primary outcome [3] 0 0
Clinical no evidence of disease activity (NEDA) as measured by the proportion of participants with no relapses
Timepoint [3] 0 0
Up to 5 years
Primary outcome [4] 0 0
Clinical NEDA as measured by the proportion of participants with no disability progression
Timepoint [4] 0 0
Up to 5 years
Secondary outcome [1] 0 0
Prescription and utilization patterns as measured by prescribed dosing frequency
Timepoint [1] 0 0
Up to 5 years
Secondary outcome [2] 0 0
Prescription and utilization patterns as measured by duration of Plegridy use
Timepoint [2] 0 0
Up to 5 years
Secondary outcome [3] 0 0
Prescription and utilization patterns as measured by the primary reason for discontinuation of Plegridy
Timepoint [3] 0 0
Up to 5 years
Secondary outcome [4] 0 0
Relapse activity as measured by annualized relapse rate (ARR)
Timepoint [4] 0 0
Up to 5 years
Secondary outcome [5] 0 0
Relapse activity as measured by time to first relapse
Timepoint [5] 0 0
Up to 5 years
Secondary outcome [6] 0 0
Relapse activity as measured by the proportion of participants with relapse
Timepoint [6] 0 0
Up to 5 years
Secondary outcome [7] 0 0
Relapse activity as measured by the distribution of the number of relapses
Timepoint [7] 0 0
Up to 5 years
Secondary outcome [8] 0 0
Disability progression as measured by the proportion of participants with sustained progression for at least six months
Timepoint [8] 0 0
Up to 5 years
Secondary outcome [9] 0 0
Disability progression as measured by the time to sustained disability progression for at least six months
Timepoint [9] 0 0
Up to 5 years
Secondary outcome [10] 0 0
Incidence proportion of non-serious AEs leading to treatment discontinuation
Timepoint [10] 0 0
Up to 5 years
Secondary outcome [11] 0 0
Incidence rate of non-serious AEs leading to treatment discontinuation
Timepoint [11] 0 0
Up to 5 years
Secondary outcome [12] 0 0
Impact of the severity of FLS on the ability to successfully manage symptoms via prophylaxis as measured by the participant-reported FLS-VAS
Timepoint [12] 0 0
Up to 5 years
Secondary outcome [13] 0 0
Changes in FLS assessment and FLS-VAS over time
Timepoint [13] 0 0
Baseline to 5 years
Secondary outcome [14] 0 0
Changes in EuroQoL EQ-5D, 3-level (EQ-5D-3L) score over time
Timepoint [14] 0 0
Baseline to 5 years
Secondary outcome [15] 0 0
Treatment adherence as measured by changes in adherence over time as reported in the treatment adherence questionnaires
Timepoint [15] 0 0
Baseline to 5 years
Secondary outcome [16] 0 0
Frequency of MS-related and non-MS-related physician visits, specialists' visits, use of physiotherapy, hospitalizations and lengths of stay, and emergency room/department visits
Timepoint [16] 0 0
Up to 5 years

Eligibility
Key inclusion criteria
Key

* Patient with MS who is newly, or is currently, prescribed Plegridy according to local label including patients who participated in Study 105MS302 (NCT01332019) or Study 105MS303 (NCT01939002).
* Patient willing and able to complete patient-reported outcomes (PRO) with minimal assistance.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Concurrent enrollment in any clinical trial of an investigational product. Participation in non-interventional study can be allowed as long as this participation does not interfere with this protocol or is likely to affect the subject's ability to comply with the protocol.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/11/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/01/2022
Sample size
Target
Accrual to date
Final
1208
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Research Site - Camperdown
Recruitment hospital [2] 0 0
Research Site - New Lambton Heights
Recruitment hospital [3] 0 0
Research Site - Auchenflower
Recruitment hospital [4] 0 0
Research Site - Bedford Park
Recruitment hospital [5] 0 0
Research Site - Fitzroy
Recruitment hospital [6] 0 0
Research Site - Heidelberg
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [3] 0 0
4066 - Auchenflower
Recruitment postcode(s) [4] 0 0
5042 - Bedford Park
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maine
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
Montana
Country [19] 0 0
United States of America
State/province [19] 0 0
New Hampshire
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New Mexico
Country [22] 0 0
United States of America
State/province [22] 0 0
New York
Country [23] 0 0
United States of America
State/province [23] 0 0
North Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Oregon
Country [27] 0 0
United States of America
State/province [27] 0 0
Pennsylvania
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
Tennessee
Country [30] 0 0
United States of America
State/province [30] 0 0
Texas
Country [31] 0 0
United States of America
State/province [31] 0 0
Utah
Country [32] 0 0
United States of America
State/province [32] 0 0
Virginia
Country [33] 0 0
United States of America
State/province [33] 0 0
Wisconsin
Country [34] 0 0
Austria
State/province [34] 0 0
Linz
Country [35] 0 0
Austria
State/province [35] 0 0
Vienna
Country [36] 0 0
Canada
State/province [36] 0 0
Alberta
Country [37] 0 0
Canada
State/province [37] 0 0
New Brunswick
Country [38] 0 0
Canada
State/province [38] 0 0
Nova Scotia
Country [39] 0 0
Canada
State/province [39] 0 0
Ontario
Country [40] 0 0
Canada
State/province [40] 0 0
Quebec
Country [41] 0 0
Denmark
State/province [41] 0 0
Esbjerg
Country [42] 0 0
Denmark
State/province [42] 0 0
Glostrup
Country [43] 0 0
Denmark
State/province [43] 0 0
Sonderborg
Country [44] 0 0
France
State/province [44] 0 0
Gard
Country [45] 0 0
France
State/province [45] 0 0
Haute Garonne
Country [46] 0 0
France
State/province [46] 0 0
Herault
Country [47] 0 0
France
State/province [47] 0 0
Ille Et Vilaine
Country [48] 0 0
France
State/province [48] 0 0
Sarthe
Country [49] 0 0
France
State/province [49] 0 0
Var
Country [50] 0 0
France
State/province [50] 0 0
Vienne
Country [51] 0 0
France
State/province [51] 0 0
Yvelines
Country [52] 0 0
France
State/province [52] 0 0
Gonesse
Country [53] 0 0
Germany
State/province [53] 0 0
Baden Wuerttemberg
Country [54] 0 0
Germany
State/province [54] 0 0
Bayern
Country [55] 0 0
Germany
State/province [55] 0 0
Brandenburg
Country [56] 0 0
Germany
State/province [56] 0 0
Hessen
Country [57] 0 0
Germany
State/province [57] 0 0
Niedersachsen
Country [58] 0 0
Germany
State/province [58] 0 0
Nordrhein Westfalen
Country [59] 0 0
Germany
State/province [59] 0 0
Rheinland Pfalz
Country [60] 0 0
Germany
State/province [60] 0 0
Sachsen
Country [61] 0 0
Germany
State/province [61] 0 0
Schleswig Holstein
Country [62] 0 0
Germany
State/province [62] 0 0
Thueringen
Country [63] 0 0
Germany
State/province [63] 0 0
Berlin
Country [64] 0 0
Germany
State/province [64] 0 0
Hamburg
Country [65] 0 0
Ireland
State/province [65] 0 0
Dublin
Country [66] 0 0
Italy
State/province [66] 0 0
Bergamo
Country [67] 0 0
Italy
State/province [67] 0 0
Cagliari
Country [68] 0 0
Italy
State/province [68] 0 0
Catanzaro
Country [69] 0 0
Italy
State/province [69] 0 0
Firenze
Country [70] 0 0
Italy
State/province [70] 0 0
Genova
Country [71] 0 0
Italy
State/province [71] 0 0
Messina
Country [72] 0 0
Italy
State/province [72] 0 0
Milano
Country [73] 0 0
Italy
State/province [73] 0 0
Napoli
Country [74] 0 0
Italy
State/province [74] 0 0
Roma
Country [75] 0 0
Netherlands
State/province [75] 0 0
Blaricum
Country [76] 0 0
Netherlands
State/province [76] 0 0
Breda
Country [77] 0 0
Netherlands
State/province [77] 0 0
Hoorn
Country [78] 0 0
Portugal
State/province [78] 0 0
Guimarães
Country [79] 0 0
Portugal
State/province [79] 0 0
Setúbal
Country [80] 0 0
Spain
State/province [80] 0 0
Cadiz
Country [81] 0 0
Spain
State/province [81] 0 0
Cordoba
Country [82] 0 0
Spain
State/province [82] 0 0
Málaga
Country [83] 0 0
Spain
State/province [83] 0 0
Sevilla
Country [84] 0 0
Switzerland
State/province [84] 0 0
Aarau
Country [85] 0 0
Switzerland
State/province [85] 0 0
Basel
Country [86] 0 0
Switzerland
State/province [86] 0 0
Bern
Country [87] 0 0
Switzerland
State/province [87] 0 0
Luzern
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Ayrshire
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Cornwall
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Greater London
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Greater Manchester
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Highland Region
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Leicestershire
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Strathclyde
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Biogen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice. The secondary objectives of this study in this study population are to describe Plegridy prescription and utilization adherence patterns in routine clinical practice; to assess the specific long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice; to monitor the safety and tolerability of Plegridy in routine clinical practice by assessing the incidence of adverse events (AEs) of flu-like symptoms (FLS), injection site reactions (ISRs), and AEs (including laboratory abnormalities) leading to treatment discontinuation; to assess the effect of FLS on participant-reported effectiveness of, and satisfaction with, prophylactic management using a FLS-Visual Analog Scale (FLS-VAS); to evaluate the change in health-related quality of life (HRQoL), FLS, FLS-VAS, healthcare resource consumption, and treatment adherence over time.
Trial website
https://clinicaltrials.gov/study/NCT02230969
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Biogen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02230969